ReviewDigestive diseases and sciences2010
Autoantibodies as prognostic markers in autoimmune liver disease.
Review in Digestive diseases and sciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 74 citations in OpenAlex.
- Liver Disease and Sickle Cell Disease: Auto-Immune Hepatitis more than a Coincidence; A Systematic Review of the Literature.Mediterranean journal of hematology and infectious diseases · 2023Review
- Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases.Journal of translational autoimmunity · 2022Article
- [Research progress of autoantibodies in primary biliary cholangitis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Article
- Potential triggering factors of acute liver failure as a first manifestation of autoimmune hepatitis-a single center experience of 52 adult patients.World journal of gastroenterology · 2018Article
- Antihistone Autoantibodies in Dobermans With Hepatitis.Journal of veterinary internal medicine · 2017Article
- Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis.Digestive diseases and sciences · 2017Review
- The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantation.Clinical and experimental hepatology · 2016Article
- Autoimmune liver disease: evaluating overlapping and cross-over presentations-a case-based discussion.Frontline gastroenterology · 2016Article
- Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions.Gut and liver · 2016Review
- Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.Digestive diseases and sciences · 2015Review
- Autoimmune hepatitis.Frontiers of medicine · 2015Review
- Medullary thymic epithelial cells and central tolerance in autoimmune hepatitis development: novel perspective from a new mouse model.International journal of molecular sciences · 2015Review
- Challenges in the diagnosis and management of autoimmune hepatitis.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013Review
- Medullary thymic epithelial cell depletion leads to autoimmune hepatitis.The Journal of clinical investigation · 2013Article
- Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis.Auto- immunity highlights · 2013Review
- Involvement of (IgG and IgM)-secreting B lymphocytes in severity of autoimmune hepatitis type 1.Medical microbiology and immunology · 2013Article
- Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.Hepatology international · 2013Article
- Development of a recombinant cell-based indirect immunofluorescence assay for the determination of autoantibodies against soluble liver antigen in autoimmune hepatitis.Clinical & developmental immunology · 2013Article
- Current concepts in the diagnosis and management of autoimmune hepatitis.Frontline gastroenterology · 2013Review
- Overlapping of primary biliary cirrhosis and small duct primary sclerosing cholangitis: first case report.Journal of clinical medicine research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Certain autoantibodies in autoimmune liver disease have prognostic implications that are under-utilized and under-developed. The goals of this review are to indicate progress in characterizing the autoantibodies with prognostic connotations and to indicate the feasibility and importance of discovering other markers. Prime source and review articles in English were selected by a Medline search through 2010. Antibodies to soluble liver antigen, actin, liver cytosol type 1, asialoglycoprotein receptor, chromatin, cyclic citrullinated peptide, and uridine glucuronosyltransferases have been associated with the occurrence, severity, and progression of autoimmune hepatitis, and antibodies to Sp100, gp210, and centromere have had similar implications in primary biliary cirrhosis. Antibodies to soluble liver antigen have shown the most promise in autoimmune hepatitis as they have been associated with severe histological changes, long durations of treatment, relapse after drug withdrawal, and high frequency of liver failure. Antibodies to the nuclear rim pore protein, gp210, have shown the most promise in primary biliary cirrhosis as they have been associated with severe interface hepatitis, lobular inflammation, and progression to liver failure. The major limitations of the autoantibodies have been their lack of standardized assays, low negative predictabilities, and fluctuating levels. Performance parameters will improve as critical pathogenic pathways, comprehensive testing batteries, and standardized assays through international exchange workshops are developed. Progress has been made in identifying the serological markers of prognosis in autoimmune liver disease, and they promise to reflect critical disease mechanisms and enhance patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.